{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:20:52Z","timestamp":1787998852088,"version":"build-2784847793"},"reference-count":37,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1080\/13543784.2020.1819981","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:33:29Z","timestamp":1599132809000},"page":"1179-1185","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1"],"prefix":"10.1080","volume":"29","author":[{"given":"Justin D.","family":"Lu","sequence":"first","affiliation":[{"name":"Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Milakovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Physiopathology and Transplantation, Universit\u00e0 Degli Studi Di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Department of dermatology, Mayo clinic, Rochester, Minnesota. USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-19"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.20022083.x"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02128.x"},{"key":"cit0004","doi-asserted-by":"crossref","unstructured":"Jockenh\u00f6fer F, Wollina U, Salva KA, et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019;180(3):615\u2013620.","DOI":"10.1111\/bjd.16401"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5980"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.019"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03199.x"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-018-0224-y"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.130"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19027"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00311.x"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1976.01630370072023"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198003000-00003"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1982.tb11684.x"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15226"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1038\/nature12174"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01980"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12989"},{"key":"cit0019","doi-asserted-by":"crossref","unstructured":"Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179(2):413\u2013419.","DOI":"10.1111\/bjd.16428"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283564"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402354"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.09.009"},{"key":"cit0023","doi-asserted-by":"crossref","unstructured":"Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp Dermatol. 2020;29(1):86\u201392.","DOI":"10.1111\/exd.14056"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18877"},{"key":"cit0025","unstructured":"InflaRx. Efficacy and safety study of IFX-1 in patients with moderate to severe hidradenitis suppurativa (HS) (SHINE). NLM identifier: NCT03487276. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03487276?term=IFX-1&draw=2&rank=4"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1506083"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14037"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01059"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.139"},{"key":"cit0032","unstructured":"Guo R, Riedemann NC. Treatment of inflammatory diseases with inhibitors of C5A activity. United States patent US 0061202 A1. 2020 Feb 27."},{"key":"cit0033","unstructured":"Guo R, Riedemann NC. Treatment of C5A for the treatment of viral pneumonia. United States patent US 0202900 A1. 2019 Jul 4."},{"key":"cit0034","unstructured":"InflaRx. Clinical assessment of safety and tolerability of the new monoclonal humanized antibody CaCP29. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01319903?term=IFX-1&draw=2&rank=9"},{"key":"cit0035","unstructured":"InflaRx. InflaRx reports additional analysis of the SHINE phase IIb results for IFX-1 in Hidradenitis Suppurativa. [cited 2020 Jul 6]. Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/07\/18\/1884908\/0\/en\/InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa.html"},{"key":"cit0036","unstructured":"InflaRx. InflaRx announces positive initial data from ongoing phase IIa open label study with IFX-1 in patients suffering from pyoderma gangraenosum. [cited 2020 Aug 28]. Available from: www.inflarx.de\/Home\/Investors\/Press-Releases\/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-html"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70199-P"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1819981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:28:49Z","timestamp":1620451729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1819981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.1080\/13543784.2020.1819981"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1819981","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}